Voglibose
Generic Details
Generic Name
Voglibose
Other Names
Drug Class
- Alpha-glucosidase inhibitor
Chemical Formula
C24H31NO7
Molecular Weight
457.51 g/mol
Mechanism of Action
- Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and absorption.
Indications
- Type 2 Diabetes Mellitus
Common Dosage Forms
- Tablet
Typical Dosage
- 0.2-0.3 mg three times a day before meals
Pediatric Dosage
- Not established
Geriatric Dosage
- Adjust dosage based on renal function
Side Effects
- Flatulence
- Diarrhea
- Abdominal pain
- Hypoglycemia (rare)
Contraindications
- Hypersensitivity to voglibose
- Inflammatory bowel disease
- Severe renal impairment
Pregnancy Category
- Category B - Animal reproduction studies have failed to demonstrate a risk to the fetus.
Lactation Safety
- Use with caution or avoid while breastfeeding
Drug Interactions
- Metformin
- Sulfonylureas
- Insulin
Overdose Symptoms
- Hypoglycemia
Antidote for Overdose
- Glucose or sugary foods
Storage Conditions
- Store at room temperature away from moisture and heat
Pharmacokinetics
- Absorption: Well absorbed after oral administration
- Distribution: Binds minimally to plasma proteins
- Metabolism: Metabolized in the intestine and liver
- Excretion: Primarily excreted unchanged in the urine
Precautions
- Monitor renal function periodically
- Caution in patients with intestinal disorders
Warnings
- Risk of hypoglycemia is higher when used in combination with other antidiabetic agents